Please login to the form below

Not currently logged in
Email:
Password:

Jazz Pharma

This page shows the latest Jazz Pharma news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy. ... The latest from pharma, biotech and healthcare. Jazz Pharma gains EU approval for niche AML treatment.

Latest news

  • Jazz Pharma bags FDA approval for rare disease drug Jazz Pharma bags FDA approval for rare disease drug

    Jazz Pharma bags FDA approval for rare disease drug. Defitelio given the green light to treat patients who develop severe hepatic VOD. ... The US FDA has given the green light for Jazz Pharma's Defitelio, adding another product to the company's stable of

  • Baxter buoys cancer presence with $900m Oncaspar deal Baxter buoys cancer presence with $900m Oncaspar deal

    disease therapy sector, with suggestions Shire or Jazz Pharma may be interested in the unit.

  • Shire drawn into Luxembourg tax haven exposé Shire drawn into Luxembourg tax haven exposé

    Investigations into Luxembourg's tax activities certainly stretch back several years, and this is not the first time that a pharma company has been implicated in the practice. ... Other pharma companies appearing in an ICIJ database of leaked documents -

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    Jazz offers $1bn for Italy's Gentium. Will gain access to recently-approved liver drug Defitelio. ... Jazz expects to achieve revenues of around $870m this year, with around $570m of that total coming from Xyrem.

  • Pharma deals for April 2012 Pharma deals for April 2012

    800. Mustafa Nevzat Pharma / Amgen. Acquisition. Turkish generics company with MEA and CEE presence. ... 700. EUSA Pharma / Jazz Pharmaceuticals. Acquisition. ERW inaze for treatment for acute lymphoblastic leukaemia  (ALL).

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    $11m. Servier. Sorrento. $821m. $28m. Jazz Pharma. Pfenex. $181m. $15m. ONO Pharma. ... Sprint BioScience/ Petre Pharma. PIP4K2a inhibitor programme. Licence. 240. Pfenex/ Jazz Pharmaceuticals.

  • Pharma deals in March 2015 Pharma deals in March 2015

    The other deal of interest is the re-emergence of EUSA Pharma with products acquired from Jazz Pharmaceuticals. ... investor, Essex Woodlands, has bought back products worth $27m and the EUSA Pharma name from Jazz for an undisclosed amount.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics